An analysis of more than 10,000 gliomas and clinical outcomes found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
An analysis of more than 10,000 gliomas and clinical outcomes found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.